BIIB•benzinga•
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Summary
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2024 by benzinga